Cencora
Change company
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
IE
US
US
US
US
IN
US
US
US
US
US
US
US
US
US
US
US
US
US
AU
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
JP
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
BM
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
CA
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
CA
US
US
US
US
US
US
US
US
US
US
US
US
US
US
Track Cencora in real time with a live news feed covering Cencora stock news, official press releases, company announcements, and an archive of historical Cencora news. ...more
Loading news...
Loading more...
2:22 PM | Sunday | Aug 23, 2026
Sign in to download news snippet
Invesco Discovery Mid Cap Growth Fund had a positive return and outperformed its benchmark in the second quarter. The fund was underweight in the communication services, health care and consumer discretionary sectors. Strong stock selection and an overweight in IT added to relative return. Weakness in energy partially offset the favorable results.
Read full articleNo data available for this time period.
Change the time range to see results.
Invesco Discovery Mid Cap Growth Fund had a positive return and outperformed its benchmark in the second quarter. The fund was underweight in the communication services, health care and consumer discretionary sectors. Strong stock selection and an overweight in IT added to relative return. Weakness in energy partially offset the favorable results.
Read full article
Invesco Discovery Mid Cap Growth Fund had a positive return and outperformed its benchmark in the second quarter. The fund was underweight in the communication services, health care and consumer discretionary sectors. Strong stock selection and an overweight in IT added to relative return. Weakness in energy partially offset the favorable results.
Read full article
Advisors Capital Management LLC purchased a new stake in shares of Cencora, Inc. (NYSE: COR) in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 2,644 shares of the company's stock, valued at approximately $748,000. Several other hedge funds and
Read full article
These healthcare companies can actually benefit from inflation.
Read full article
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read full article
Shares of Cencora, Inc. (NYSE: COR - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the fifteen research firms that are presently covering the stock, Marketbeat reports. Two research analysts have rated the stock with a hold recommendation and thirteen have assigned a buy recommendation to the company. The average 1-year
Read full article
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read full article
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read full article
Allspring Growth Fund outperformed the Russell 3000 Growth Index during the quarter. Sandisk Corp. is riding the AI storage super-cycle. Shares of Cencora could not distribute in a 'risk-on' market.
Read full article
Cencora NYSE: COR reported fiscal 2026 third-quarter results marked by double-digit adjusted operating income growth, specialty-business momentum and $1 billion in share repurchases, prompting the pharmaceutical services company to raise its full-year adjusted earnings outlook.
Read full article
Cencora's fiscal Q3 EPS beats estimates as broad segment growth lifts profit, prompting a higher 2026 outlook despite a slight revenue miss.
Read full article
No data available for this time period.
Change the time range to see results.